An Open-label Early Access Phase IIIb Study of Trifluridine / Tipiracil (S 95005/TAS-102) in Patients With a Pretreated Metastatic Colorectal Cancer (PRECONNECT)
Latest Information Update: 14 Feb 2023
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Expanded access; Registrational
- Acronyms PRECONNECT
- Sponsors Servier
- 27 Jan 2023 Results assessing safety and efficacy of trifluridine/tipiracil (FTD/TPI) for metastatic colorectal cancer published in the BMC Cancer
- 03 Jul 2021 Final results from PRECONNECT according to duration of treatment, presented at the 23rd World Congress on Gastrointestinal Cancer
- 07 Dec 2020 Status changed from active, no longer recruiting to completed.